Stryker Corp. (SYK) Director Ronda E. Stryker Sells 12,000 Shares
Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 13th. The stock was sold at an average price of $113.41, for a total value of $1,360,920.00. Following the transaction, the director now owns 193,142 shares in the company, valued at approximately $21,904,234.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Stryker Corp. (NYSE:SYK) opened at 113.58 on Friday. The stock has a 50 day moving average price of $115.21 and a 200-day moving average price of $114.05. The stock has a market cap of $42.51 billion, a P/E ratio of 26.78 and a beta of 0.72. Stryker Corp. has a 12 month low of $86.68 and a 12 month high of $123.55.
Stryker Corp. (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 21st. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.37 by $0.02. The business earned $2.84 billion during the quarter, compared to the consensus estimate of $2.79 billion. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.33%. On average, analysts forecast that Stryker Corp. will post $5.76 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be given a dividend of $0.38 per share. The ex-dividend date of this dividend is Wednesday, September 28th. This represents a $1.52 annualized dividend and a dividend yield of 1.34%. Stryker Corp.’s dividend payout ratio is presently 35.85%.
A number of research firms have weighed in on SYK. SunTrust Banks Inc. began coverage on Stryker Corp. in a research report on Thursday. They set a “buy” rating for the company. Zacks Investment Research cut Stryker Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, September 27th. Brean Capital reaffirmed a “buy” rating and set a $125.00 price objective (up from $121.00) on shares of Stryker Corp. in a research report on Monday, July 25th. Jefferies Group reaffirmed a “hold” rating and set a $120.00 price objective (up from $113.00) on shares of Stryker Corp. in a research report on Monday, July 25th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $130.00 price objective on shares of Stryker Corp. in a research report on Sunday, July 24th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $114.91.
Several institutional investors have recently modified their holdings of the company. LSV Asset Management purchased a new stake in Stryker Corp. during the second quarter worth $107,000. Global X Management Co. LLC increased its stake in Stryker Corp. by 235.8% in the second quarter. Global X Management Co. LLC now owns 994 shares of the medical technology company’s stock worth $119,000 after buying an additional 698 shares during the period. Carroll Financial Associates Inc. increased its stake in Stryker Corp. by 78.0% in the second quarter. Carroll Financial Associates Inc. now owns 1,086 shares of the medical technology company’s stock worth $130,000 after buying an additional 476 shares during the period. CWM LLC purchased a new stake in Stryker Corp. during the second quarter worth $150,000. Finally, Daiwa SB Investments Ltd. purchased a new stake in Stryker Corp. during the third quarter worth $163,000. Institutional investors and hedge funds own 75.49% of the company’s stock.
About Stryker Corp.
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.